Innovent Biologics of Suzhou reported that its IND application for IBI-188, a fully human anti-CD47 mAb drug candidate, has been approved to start US clinical trials in patients with advanced malignancies and lymphomas. Last month, China approved clinical trials for the same candidate. The candidate is Innovent’s second molecule approved for US trials. The other, also an immunotherapy, is an anti-PD-1 antibody. Innovent is the first Chinese biopharma to be granted clinical trial approval for an anti-CD47 immunotherapy from the US FDA.
Source: China Biotoday
